Tonix Pharmaceuticals reports sales growth following Medicare agreements
1 report, 1 independent
Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Tonix Pharmaceuticals secured managed agreements with Medicare. The company reported approximately $15 million in third-quarter sales for its fibromyalgia drug TONMYA, which was 37% higher than the previous quarter. Total net product revenue reached $17.2 million, up from $3.3 million a year earlier.
From dailypolitical.com
Why it matters
The expanded insurance coverage, including agreements with Medicare, contributed to increased prescriptions for TONMYA. The company attributes the revenue growth to these payer agreements and favorable gross-to-net adjustments.
From dailypolitical.com
Who's involved
- Tonix PharmaceuticalsCommercial pharmaceutical company that reported sales growth
- MedicareUS federal health insurance program that signed managed agreements
- Seth LedermanChief Executive Officer of Tonix Pharmaceuticals
Keep exploring
The entities involved
-
Tonix Pharmaceuticals
commercial pharmaceutical company
-
Medicare
US federal health insurance
-
Seth Lederman
American pharmacologist
Nothing else this week.